Oren Hershkovitz
Chief Executive Officer at ENLIVEX THERAPEUTICS LTD.
Net worth: 72 605 $ as of 31/03/2024
Profile
Oren Hershkovitz is the Chief Executive Officer at Enlivex Therapeutics Ltd.
and also serves as the Director & General Manager at OPKO Biologics Ltd.
He holds a doctorate degree from Ben-Gurion University of the Negev.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/03/2023 | 19,157 ( 0.10% ) | 72 605 $ | 31/03/2024 |
Oren Hershkovitz active positions
| Companies | Position | Start |
|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Chief Executive Officer | 16/11/2019 |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Director/Board Member | 01/09/2016 |
Training of Oren Hershkovitz
| Ben-Gurion University of the Negev | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| Private companies | 1 |
|---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Health Technology |
- Stock Market
- Insiders
- Oren Hershkovitz
